{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Merus NV Hits New 52-Week High of $95.06, Up 77.91%
Merus NV has achieved a new 52-week high, reflecting a strong performance with a significant stock appreciation over the past year. As a small-cap company in the Pharmaceuticals & Biotechnology sector, it has a market capitalization of over USD 5 billion, showcasing resilience in a competitive landscape.
Merus NV Hits New 52-Week High of $95.02, Up 77.85%
Merus NV achieved a new 52-week high of USD 95.02 on October 13, 2025, reflecting a significant increase over the past year. With a market capitalization of USD 5,082 million, the company remains unprofitable, indicated by its negative price-to-earnings ratio and a high price-to-book ratio.
Merus NV Experiences Revision in Stock Evaluation Amid Strong Market Performance
Merus NV, a small-cap pharmaceutical and biotechnology company, is currently trading at 94.37, slightly below its previous close. The stock has shown significant outperformance against the S&P 500 over the past year and year-to-date, indicating a strong market position despite mixed technical indicators.
Merus NV Hits Day High with 36.67% Surge in Intraday Performance
Merus NV, a small-cap biotechnology firm, saw significant stock activity on September 30, 2025, with a notable intraday high. The company has demonstrated impressive long-term gains, outperforming major indices, but faces challenges such as declining net sales and negative operating cash flow, indicating potential financial risks.
Is Merus NV technically bullish or bearish?
As of September 11, 2025, Merus NV's technical trend is bullish, supported by positive MACD readings and a strong year-to-date return of 63.97%, significantly outperforming the S&P 500's 12.22%.
Is Merus NV overvalued or undervalued?
As of November 7, 2016, Merus NV is considered risky and overvalued due to its high Price to Book Value of 7.02, negative EV to EBIT and EV to EBITDA ratios, and a concerning ROCE of -215.67%, despite a strong year-to-date stock performance of 63.97%.
Is Merus NV overvalued or undervalued?
As of November 7, 2016, Merus NV is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 7.02, negative EV to EBITDA of -12.49, and significantly negative returns, while its stock performance has lagged behind the S&P 500.
Is Merus NV technically bullish or bearish?
As of June 17, 2025, Merus NV's technical trend is mildly bullish, supported by a bullish weekly MACD and moving averages, despite mixed signals from monthly indicators and a mildly bearish weekly Dow Theory.
Who are in the management team of Merus NV?
As of March 2022, the management team of Merus NV includes Dr. Anand Mehra (Non-Executive Independent Chairman), Dr. Sven Lundberg (CEO), Mr. Gregory Perry (Independent Non-Executive Vice Chairman), and several Non-Executive Independent Directors: Mr. Mark Iwicki, Mr. Leonard Kanavy, and Mr. Paolo Pucci. They oversee the company's strategic direction and governance.
What does Merus NV do?
Merus NV is a Netherlands-based biotechnology company focused on developing cancer therapeutics, with recent net sales of $26 million and a net loss of $96 million. It has a market cap of approximately $3.95 billion and operates as a small-cap company.
How big is Merus NV?
As of Jun 18, Merus NV has a market capitalization of 3,953.23 million, classifying it as a Small Cap company, with net sales of 54.73 million and a net profit of -277.34 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
